2269.HK WuXi Biologics
HK$52.35 -3.23%
Asia ·
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-3.23%
YTD
+24.60%
P/E
—
P/B
—
ROE
—
Div yield
—
Beta
0.39
Market cap
—
RSI (14)
51
Next earnings
—
Previous session
close of Oct 9, 2026 · EOD, no live order bookOpen
HK$56.70
Close
HK$52.35
VWAP (n/a)
—
Day high
HK$57.25
Day low
HK$53.80
Volume
35.3M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Recombinant Proteins Manufacturing Services Market Report Released; 19.7% CAGR as revenue nearly triples from $5.2B to $15.3B by 2030; benchmark WuXi Biologics, GenScript, Bio-Rad, ACROBiosystems and Syngene amid tariff disruption
Yahoo Finance · Oct 1
WuXi Biologics Passes Another FDA GMP Inspection, Reinforcing Its Quality Track Record and Commercial Supply Reliability
Yahoo Finance · Sep 24
WuXi Biologics Named to Forbes China ESG 50 List 2026 for Green CRDMO and Digital ESG Leadership
Yahoo Finance · Sep 16
WuXi Biologics Reports Strong Profitable Growth in H1 2026
Yahoo Finance · Aug 25
WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
Yahoo Finance · Aug 18
Is WuXi Biologics (Cayman) (SEHK:2269) Still Below Fair Value On FTSE4Good Recognition?
Yahoo Finance · Jul 31
Headlines via Yahoo Finance · links open the source · not an endorsement.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell 2269.HK. Try it in the Lab to size a position and see the risk.